Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(3.15)
# 1,167
Out of 5,124 analysts
107
Total ratings
38.61%
Success rate
15.8%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XOMA XOMA Royalty | Initiates: Buy | $76 | $27.99 | +171.53% | 1 | Dec 9, 2025 | |
| SAVA Cassava Sciences | Initiates: Buy | $8 | $2.09 | +282.78% | 2 | Oct 6, 2025 | |
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $1.70 | +3,782.35% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.24 | +4,902.08% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $3.38 | +402.96% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $3.00 | +266.67% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $66.01 | -24.25% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.49 | +1,040.94% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $220 | $6.96 | +3,060.92% | 1 | Aug 19, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $1.47 | +852.38% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $67 | $3.65 | +1,735.62% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $16.59 | +159.19% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.65 | +218.58% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.07 | +600.93% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $3.87 | +287.60% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $13.64 | +53.96% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $6.55 | +480.15% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $1.19 | +3,261.34% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $5.80 | +762.07% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $8.28 | +1,276.81% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $5.77 | +3,366.20% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $13.24 | +149.24% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $25.86 | +54.68% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.22 | +2,932.79% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $7.93 | +303.53% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $6.25 | +1,132.00% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.87 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $67.79 | -26.24% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $4.67 | +606.64% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $15.38 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $16.38 | +58.73% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $246.91 | -88.66% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $5.31 | +15,907.53% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $11.82 | +77.66% | 2 | Jul 12, 2017 |
XOMA Royalty
Dec 9, 2025
Initiates: Buy
Price Target: $76
Current: $27.99
Upside: +171.53%
Cassava Sciences
Oct 6, 2025
Initiates: Buy
Price Target: $8
Current: $2.09
Upside: +282.78%
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $1.70
Upside: +3,782.35%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.24
Upside: +4,902.08%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $3.38
Upside: +402.96%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $3.00
Upside: +266.67%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $66.01
Upside: -24.25%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.49
Upside: +1,040.94%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $220
Current: $6.96
Upside: +3,060.92%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $1.47
Upside: +852.38%
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $3.65
Upside: +1,735.62%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $16.59
Upside: +159.19%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $5.65
Upside: +218.58%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.07
Upside: +600.93%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $3.87
Upside: +287.60%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $13.64
Upside: +53.96%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $6.55
Upside: +480.15%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $1.19
Upside: +3,261.34%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $5.80
Upside: +762.07%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $8.28
Upside: +1,276.81%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $5.77
Upside: +3,366.20%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $13.24
Upside: +149.24%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $25.86
Upside: +54.68%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.22
Upside: +2,932.79%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $7.93
Upside: +303.53%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $6.25
Upside: +1,132.00%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.87
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $67.79
Upside: -26.24%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $4.67
Upside: +606.64%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $15.38
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $16.38
Upside: +58.73%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $246.91
Upside: -88.66%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $5.31
Upside: +15,907.53%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $11.82
Upside: +77.66%